Igc receives no objection letter from health canada

Potomac, md., jan. 04, 2023 (globe newswire) -- via investorwire -- india globalization capital, inc. (nyse american: igc) (“igc” or the “company”) today announces it has received a no objection letter from health canada for approval of its trial, “a phase 2, multi-center, double-blind, randomized, placebo-controlled trial of the safety and efficacy of igc-ad1 on agitation in participants with dementia due to alzheimer's disease.” the no objection letter provides the acknowledgement of igc-ad1's drug candidacy and the authority to proceed with phase 2 trials in canada.
IGC Ratings Summary
IGC Quant Ranking